Your session is about to expire
← Back to Search
Pazopanib + PCI-24781 for Metastatic Cancer
Study Summary
This trial is testing a new cancer drug to see if it is safe and works well against solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From undefined Phase 1 & 2 trial • 55 Patients • NCT00724984Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had any cancer except for skin cancer in the last 5 years.I have serious stomach or intestine problems that could cause bleeding.I do not have active hepatitis C or B, HIV, or any uncontrolled infection.My cancer is advanced, confirmed by lab tests, and matches the specific types needed for Phase Ib.My cancer has spread to my brain or spinal cord.I have no major stomach or intestine problems that affect medication absorption.I haven't had heart problems in the last 6 months.My high blood pressure is not well-managed.I have a history of cancer.I am currently being treated for another cancer besides the one being studied.I have had a stroke or a mini-stroke.I have not had major surgery or serious injury in the last 28 days.It's been over 4 weeks or five half-lives since my last cancer treatment.I am a woman who either can or cannot become pregnant, following specific criteria.I can stop taking certain medications for 14 days or five half-lives (whichever is shorter) before starting the study drug.I am 18 years old or older.My cancer has spread and this was confirmed by lab tests.I am fully active or can carry out light work.All my side effects from cancer treatment are mild, except for hair loss.I am currently experiencing active bleeding or have a bleeding disorder.I have had a blood clot in my lungs or an untreated clot in my veins in the last 6 months.My organs are functioning well.I have had a condition where my lymphocytes grow abnormally.
- Group 1: Panobinostat with PC124871
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any existing opportunities for participants to join the research?
"Per the details available on clinicaltrials.gov, this research is actively attempting to find patients. The study was posted on June 25th 2012 and last edited August 24th 2022."
Is this research a pioneering endeavor into uncharted medical territory?
"Investigated since 2010, PZP115891 and PCI-24781 was initially sponsored by Secura Bio, Inc. for a Phase 1 clinical trial that included 18 patients in the same year. Subsequently approved as a drug, it is now being studied across 38 countries and 676 cities with 43 ongoing trials."
What are the primary ailments that PZP115891 and PCI-24781 have been found to ameliorate?
"According to research, PZP115891 and PCI-24781 have been demonstrated as efficacious treatments for advanced thyroid cancer, refractory multiple myeloma, and soft tissue sarcoma (STS)."
What primary goals are investigators looking to accomplish with this experiment?
"The primary end-point of this study, which will be observed over a four week period, is dose limiting toxicity (DLT). Additionally, secondary objectives include establishing the area under concentration curve (AUC), determining bioavailability and calculating volume of distribution in regards to PCI-24781, pazopanib and their combination."
How many participants are actively engaged in this experiment?
"Affirmative. Clinicaltrials.gov data reveals that this clinical experiment, whose inception was June 25th 2012, is actively seeking participants. Approximately 120 patients need to be enrolled from a single medical centre."
What potential risks does exposure to PZP115891, PCI-24781 pose for those participating in the trial?
"As this is a Phase 1 trial and thus has only minimal evidence supporting its safety and efficacy, PZP115891/PCI-24781 was awarded a score of one."
Share this study with friends
Copy Link
Messenger